ADXN Company Profile and Key Details
Addex Therapeutics Ltd
ADXN Stock Price Chart
Stock Price Today
Addex Therapeutics Ltd (ADXN) stock surged +0.26%, trading at $7.70 on NASDAQ, up from the previous close of $7.68. The stock opened at $7.74, fluctuating between $7.59 and $7.82 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Company Information
| Employees | 23 |
| Beta | 1.87 |
| Sales or Revenue | $1.61M |
| 5Y Sales Change% | -0.916% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Addex Therapeutics Ltd (NASDAQ: ADXN) stock price is $7.70 in the last trading session. During the trading session, ADXN stock reached the peak price of $7.82 while $7.59 was the lowest point it dropped to. The percentage change in ADXN stock occurred in the recent session was 0.26% while the dollar amount for the price change in ADXN stock was $0.02.
The NASDAQ listed ADXN is part of Biotechnology industry that operates in the broader Healthcare sector. Addex Therapeutics Ltd designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Werner Henrichi Ph.D.
Consultant
Mr. Timothy Mark Dyer
Co-Founder, Chief Executive Officer & Director
Dr. Roger G. Mills M.D.
Chief Medical Officer & Director
Mr. Lénaic Teyssédou
Head of Fin.
Dr. Jean-Philippe Rocher Ph.D.
Head of Discovery - Chemistry
Dr. Robert Lutjens
Head of Discovery - Biology
Dr. Mikhail Kalinichev Ph.D.
Head of Translational Science
ADXN's closing price is 10% higher than its 52-week low of $7.00 where as its distance from 52-week high of $27.90 is -72.4%.
Number of ADXN employees currently stands at 23.
Official Website of ADXN is: https://www.addextherapeutics.com
ADXN could be contacted at phone 412 288 41555 and can also be accessed through its website. ADXN operates from Chemin des Mines, 9, Geneva, 1202, Switzerland.
ADXN stock volume for the day was 6.23K shares. The average number of ADXN shares traded daily for last 3 months was 43.22K.
The market value of ADXN currently stands at $12.62M with its latest stock price at $7.70 and 1.64M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com